This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Percutaneous Aortic Valve 18F System for the Treatment of Patients With Severe Aortic Stenosis

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Direct Flow Medical, Inc. Identifier:
First received: November 17, 2011
Last updated: October 31, 2016
Last verified: October 2016
The purpose of the study is to determine the safety and performance of the Direct Flow Medical study valve and delivery procedure.

Condition Intervention
Aortic Valve Stenosis Device: Replacement of the Aortic Stenotic Valve

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of the Direct Flow Medical Percutaneous Aortic Valve 18F System for the Treatment of Patients With Severe Aortic Stenosis

Resource links provided by NLM:

Further study details as provided by Direct Flow Medical, Inc.:

Primary Outcome Measures:
  • Freedom from all-cause mortality from procedure to 30 days [ Time Frame: Procedure to 30 days ]

Secondary Outcome Measures:
  • Device Success at procedure completion [ Time Frame: At procedure completion ]
    Device success is assessed at the completion of the study procedure based on TEE

Enrollment: 112
Study Start Date: November 2011
Estimated Study Completion Date: July 2019
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Percutaneous Aortic Valve 18F System
Evaluation of the Direct Flow Medical Percutaneous Aortic Valve 18F System for the Treatment of Patients with Severe Aortic Stenosis.
Device: Replacement of the Aortic Stenotic Valve
Treatment for patients with Severe Aortic Stenosis.
Other Name: TAVR

Detailed Description:
Prospective, multicenter, non-randomized clinical trial of the Direct Flow Medical Percutaneous Aortic Valve 18F System for the treatment of severe aortic stenosis

Ages Eligible for Study:   70 Years and older   (Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

All candidates for the study must meet the following inclusion criteria:

  1. Severe aortic valve stenosis determined by echocardiogram and Doppler, defined as: mean gradient >40 mmHg or peak jet velocity >4.0 m/s and an aortic valve area ≤0.8 cm2 or aortic valve area index ≤0.5 cm2/m2
  2. Symptomatic aortic valve stenosis demonstrated by angina, congestive heart failure, NYHA Functional Class ≥ II, or syncope
  3. Patient is an extreme risk candidate for open surgical aortic valve repair such that the site Investigators (interventional cardiologist and cardiothoracic surgeon) agree that medical factors preclude operation, based on the conclusion that the probability of death or serious morbidity exceeds the probability of meaningful improvement due to the patient's co-morbidities (such as, but not limited to, severe COPD, porcelain aorta, previous thorax irradiation) or logistic EuroSCORE ≥ 20
  4. ≥ 70 years old
  5. Patient has been informed of the nature of the study and has provided written informed consent
  6. Patient and treating physician agree that the patient will return for all required post-procedure follow-up visits

Exclusion Criteria

Candidates will be excluded from the study if any of the following criteria are present:

  1. Patient is a surgical candidate for aortic valve replacement
  2. Congenital bicuspid or unicuspid valve determined by echocardiography
  3. Native valve annulus diameter is <17mm or >22mm determined by the screening CT scan
  4. Extreme asymmetrical calcification of the native aortic valve determined by the screening CT scan
  5. Native valvular or peripheral vascular anatomy is not appropriate for the DFM bioprosthesis and 18F delivery system
  6. Left ventricular ejection fraction (LVEF) <30% determined by resting echocardiogram
  7. Evidence of an acute myocardial infarction (Refer to Definitions in Section 8) within 30 days prior to the study procedure
  8. Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to the study procedure
  9. Any planned surgical or percutaneous coronary or peripheral procedure to be performed during the study procedure or prior to 30 day follow-up visit
  10. Need for emergency surgery for any reason
  11. Untreated clinically significant ( > 70% obstruction) coronary artery disease requiring revascularization
  12. Prior aortic or mitral valve surgery
  13. Pre-existing prosthetic heart valve in any position
  14. Mitral insufficiency greater than moderate determined by resting echocardiography
  15. Echocardiographic evidence of intra-cardiac mass, thrombus or vegetation
  16. Thoracic aortic aneurysm (TAA)
  17. Abdominal aortic aneurysm (AAA) >4.5 cm
  18. Presence of an endovascular stent graft for treatment of AAA or TAA
  19. Hypertrophic cardiomyopathy
  20. Hemodynamic instability (e.g. requiring inotropic support)
  21. Trans-esophageal echocardiography (TEE) is contraindicated
  22. Renal insufficiency (creatinine > 3.0 mg/dL) and/or end-stage renal disease requiring dialysis at the time of screening
  23. Active endocarditis or sepsis within 6 months prior to the study procedure
  24. Stroke or transient ischemic attack (TIA) within 6 months prior to the study procedure
  25. Cardiogenic shock within 30 days prior to the study procedure
  26. Active peptic ulcer or upper GI bleeding within 3 months prior to the study procedure
  27. Leukopenia (WBC <3000/mm³), acute anemia (Hb <9 g/dL), or thrombocytopenia (platelet count <100,000 cells/mm3)
  28. History of bleeding diathesis or coagulopathy or refusal of blood transfusions
  29. A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel, or sensitivity to contrast media, which cannot be adequately pre-medicated
  30. Currently participating in an investigational drug or another device trial
  31. Previously enrolled in this study
  32. Patient refusal of surgery
  33. Life expectancy thought to be <12 months
  34. Dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01475799

L'Institut Hospitalier Jacques Cartier
Massy, France, 91300
Clinique Pasteur
Toulouse, France, 31300
Vivantes Klinikum im Friedrichshain
Berlin, DE, Germany, 10623
University Hospital Bonn
Bonn, Germany
Elisabeth-Krankenhaus Essen, GmbH
Essen, Germany, 45138
Medical Care Center, Prof Mathey, Prof Schofer
Hamburg, Germany, 22527
Krankenhaus der Barmherzigen Brüder Trier
Trier, Germany
San Raffaele Hospital
Milan, Italy, 20132
Azienda Ospedaliera Niguarda Ca Granda
Milan, Italy
Centre hospitalier de Luxembourg
Luxembourg, Luxembourg
United Kingdom
St. Bartholomew's Hospital
London, United Kingdom, EC1A 7BE
St. Thomas' Hospital
London, United Kingdom, SE1 7EH
Sponsors and Collaborators
Direct Flow Medical, Inc.
Principal Investigator: Thierry LeFevre, M.D. Study PI
Principal Investigator: Prof. Joachim Schofer Study PI
  More Information

Responsible Party: Direct Flow Medical, Inc. Identifier: NCT01475799     History of Changes
Other Study ID Numbers: IP 010
Study First Received: November 17, 2011
Last Updated: October 31, 2016

Additional relevant MeSH terms:
Constriction, Pathologic
Aortic Valve Stenosis
Pathological Conditions, Anatomical
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction processed this record on September 19, 2017